Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 2Uterine Cervical Neoplasms 1Lung Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

Paclitaxel 81Trastuzumab 76Fulvestrant 55Cyclophosphamide 49Capecitabine 42Lapatinib 40pembrolizumab 38Docetaxel 38palbociclib 36Carboplatin 32Letrozole 28olaparib 23Doxorubicin 23Gemcitabine 21Taxes 20Everolimus 20ribociclib 19abemaciclib 19Ado-Trastuzumab Emtansine 18pertuzumab 17Radiotherapy 17Magnetic Resonance Spectroscopy 17Bevacizumab 16130-nm albumin-bound paclitaxel 16exemestane 15Vinorelbine 15Cisplatin 15veliparib 14Biopsy 14Alpelisib 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Breast Neoplasms × Adoptive Transfer × Clear all
NCT05483491 2025-03-30

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer

Rutgers, The State University of New Jersey

Phase 1 Recruiting
30 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Lung Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡